NCT05615636 2026-03-16
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
4 trialsNCT00478959 2020-09-18
Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma
University Health Network, Toronto
Phase 2 Completed
NCT01460940 2017-11-14
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00540007 2017-11-06
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
Washington University School of Medicine
Phase 2 Completed